Press release content from PR Newswire. The AP news staff was not involved in its creation.
Curaleaf Celebrates the Grand Opening of Its 100th National Retail Location
February 10, 2021 GMT
The country’s largest cannabis operator continues to expand its retail footprint, opening four new dispensaries in Florida in February
WAKEFIELD, Mass., Feb. 10, 2021 /PRNewswire/ Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the opening of Curaleaf Jacksonville San Jose, the Company’s 100th dispensary nationwide.
The opening of Curaleaf Jacksonville San Jose, located at 9760 San Jose Blvd, follows the recent opening of Curaleaf St. Petersburg North, and is the second of four new dispensaries that Curaleaf plans to open this month in Florida, one of the country’s fastest-growing medical cannabis markets. By the end of February, Curaleaf’s planned footprint will inclu
Press release content from PR Newswire. The AP news staff was not involved in its creation.
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
February 11, 2021 GMT
TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/
Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C)
In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced LDL-C by nearly half at 24 weeks, compared to placebo
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (
Press release content from Business Wire. The AP news staff was not involved in its creation.
CURE Pharmaceutical Announces Promotions and Additions to Board of Directors
February 11, 2021 GMT
OXNARD, Calif. (BUSINESS WIRE) Feb 11, 2021
CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors.
ADVERTISEMENT
After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings, Inc. an
Press release content from Business Wire. The AP news staff was not involved in its creation.
Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial
February 11, 2021 GMT
Advanced Chemotherapy Technologies ACT-IOP-003 iontophoresis chemotherapy delivery system (Photo: Business Wire)
RALEIGH, N.C. (BUSINESS WIRE) Feb 10, 2021
Advanced Chemotherapy Technologies, Inc., a clinical-stage drug delivery company, announced today that it has closed a Series A investment of $2.5 million with Spectrum Financial. This investment is in addition to the previously announced Series A investment of $5.5 million lead by Khosla Venture. The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local chemotherapy system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.